bosentan anhydrous has been researched along with Angiogenesis, Pathologic in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (33.33) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abdelsaid, M; Coucha, M; Ergul, A; Kaczmarek, J | 1 |
| Chuang, CL; Hsin, IF; Hsu, SJ; Huang, HC; Lee, FY; Lee, JY; Lee, SD; Lin, HC; Lin, TY; Wang, SS | 1 |
| Carducci, MA; Lassiter, LK | 1 |
| Jiao, WJ; Pan, H; Shen, Y; Wang, TY; Xu, J | 1 |
| Hill, NS; Klinger, JR; Pietras, L; Warburton, RR | 1 |
| Ballerini, L; Bernucci, P; Formigari, R; Grigioni, M; Marano, G; Palazzesi, S | 1 |
1 review(s) available for bosentan anhydrous and Angiogenesis, Pathologic
| Article | Year |
|---|---|
Endothelin receptor antagonists in the treatment of prostate cancer.
Topics: Androgen Antagonists; Apoptosis; Atrasentan; Bone Neoplasms; Bosentan; Clinical Trials as Topic; Disease Progression; Drug Resistance, Neoplasm; Endothelin Receptor Antagonists; Endothelins; Forecasting; Humans; Male; Neovascularization, Pathologic; Prostatic Neoplasms; Pyrimidines; Pyrrolidines; Receptors, Endothelin; Sulfonamides; Treatment Outcome | 2003 |
5 other study(ies) available for bosentan anhydrous and Angiogenesis, Pathologic
| Article | Year |
|---|---|
Dual endothelin receptor antagonism with bosentan reverses established vascular remodeling and dysfunctional angiogenesis in diabetic rats: relevance to glycemic control.
Topics: Animals; Bosentan; Diabetes Mellitus, Experimental; Endothelin Receptor Antagonists; Hyperglycemia; Middle Cerebral Artery; Neovascularization, Pathologic; Rats; Receptor, Endothelin A; Receptor, Endothelin B; Sulfonamides; Vascular Remodeling | 2014 |
Endothelin receptor blockers reduce shunting and angiogenesis in cirrhotic rats.
Topics: Animals; Bosentan; Collateral Circulation; Cyclooxygenase 2; Disease Models, Animal; Endothelin A Receptor Antagonists; Endothelin Receptor Antagonists; Hypertension, Portal; Liver Cirrhosis; Male; Neovascularization, Pathologic; Nitric Oxide Synthase Type II; Phenylpropionates; Phosphoproteins; Portal Pressure; Proto-Oncogene Proteins c-akt; Pyridazines; Random Allocation; Rats; Rats, Sprague-Dawley; RNA, Messenger; Sulfonamides; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2016 |
Effect of endothelin-1 in esophageal squamous cell carcinoma invasion and its correlation with cathepsin B.
Topics: Antihypertensive Agents; Bosentan; Carcinoma, Squamous Cell; Cathepsin B; Cell Line, Tumor; Collagen; Disease Progression; Drug Combinations; Endothelin-1; Esophageal Neoplasms; Gene Expression Regulation, Neoplastic; Humans; Laminin; Neoplasm Invasiveness; Neovascularization, Pathologic; Proteoglycans; Sulfonamides | 2007 |
Nonspecific endothelin-receptor antagonist blunts monocrotaline-induced pulmonary hypertension in rats.
Topics: Animals; Antihypertensive Agents; Bosentan; Cardiac Output; Endothelin Receptor Antagonists; Endothelin-1; Hemodynamics; Hypertension, Pulmonary; Hypertrophy, Right Ventricular; Lung; Male; Monocrotaline; Neovascularization, Pathologic; Organ Size; Poisons; Pulmonary Circulation; Rats; Rats, Sprague-Dawley; Sulfonamides | 1997 |
ET(A)/ET(B) receptor antagonist bosentan inhibits neointimal development in collared carotid arteries of rabbits.
Topics: Animals; Antihypertensive Agents; Bosentan; Carotid Arteries; Endothelin Receptor Antagonists; Hyperplasia; Male; Neovascularization, Pathologic; Rabbits; Receptor, Endothelin A; Receptor, Endothelin B; Sulfonamides | 1998 |